2026 Idiopathic gastroparesis indication strategy covering epidemiology, GHRL biology, active trials, transactions, unmet need, competition and market…

2026 Protein-losing enteropathy indication strategy covering epidemiology, VEGFR3 biology, active trials, transactions, unmet need, competition and market…

2026 Short bowel syndrome with intestinal failure indication strategy covering epidemiology, GLP-2 biology, active trials, transactions, unmet need, competition…

2026 Gastroparesis diabetic indication strategy covering epidemiology, GHRL biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Intestinal lymphangiectasia indication strategy covering epidemiology, VEGFR3 biology, active trials, transactions, unmet need, competition and market…

2026 Collagenous colitis indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Lymphocytic colitis indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Collagenous gastritis indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Eosinophilic gastroenteritis indication strategy covering epidemiology, IL-5 biology, active trials, transactions, unmet need, competition and market…

2026 Gastric antral vascular ectasia indication strategy covering epidemiology, VEGF biology, active trials, transactions, unmet need, competition and market…

2026 Portal hypertensive gastropathy indication strategy covering epidemiology, VEGF biology, active trials, transactions, unmet need, competition and market…

2026 Lean metabolic dysfunction-associated steatotic liver disease indication strategy covering epidemiology, FGF21 biology, active trials, transactions, unmet…